Table 2.
Current systemic options for advanced, inoperable GBC.
| Authors | Phase | Line of Treatment | Treatment | Median PFS (Months) | Median OS (Months) |
|---|---|---|---|---|---|
| Valle [61] ABC-02 study |
3 | 1 | GEMCIS vs. gemcitabine | 8 vs. 5 (p < 0.001) | 11.7 vs. 8.1 (p < 0.001) |
| Shroff [56] | 2 | 1 | GEMCIS + nab-paclitaxel | 11.8 | 19.2 |
| Williams [64] | 2 | 1 | Gemcitabine + carboplatin | 7.8 | 10.6 |
| Kim [65] | 3 | 1 | CAPOX vs. GEMOX (non-inferior study) |
5.8 vs. 5.3 | 10.6 vs. 10.4 (p = 0.131) |
| Lamarca [62] ABC-06 study |
3 | 2 | FOLFOX vs. symptom control | 4 vs. N/A | 6.2 vs. 5.3 (p = 0.031) |
| Yoo [63] NIFTY study |
2 | 2 | 5-FU + liposomal irinotecan | 7.1 vs. 1.4 (p = 0.0019) |
8.6 vs. 5.5 (p = 0.035) |
Abbreviations: GEMCIS = gemcitabine plus cisplatin. GEMOX = gemcitabine plus oxaliplatin. CAPOX = capecitabine plus oxaliplatin. CT = chemotherapy. RT = radiotherapy. CRT = chemoradiotherapy.